Alligator Bioscience AB Share Price London S.E.
Equities
0RK9
SE0000767188
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.508 SEK | -66.28% | +123.96% | +303.28% |
Sales 2024 * | 261M 24.82M 1.95B | Sales 2025 * | 122M 11.63M 912M | Capitalization | 817M 77.64M 6.09B |
---|---|---|---|---|---|
Net income 2024 * | -6M -570K -44.73M | Net income 2025 * | -89M -8.46M -664M | EV / Sales 2024 * | 1.62 x |
Net cash position 2024 * | 395M 37.48M 2.94B | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 6.68 x |
P/E ratio 2024 * |
-2.37
x | P/E ratio 2025 * |
-10.8
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.28% |
Latest transcript on Alligator Bioscience AB
1 day | -66.28% | ||
1 week | +123.96% | ||
Current month | +123.96% | ||
1 month | +123.96% | ||
3 months | +123.96% | ||
6 months | +497.95% | ||
Current year | +303.28% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Bregenholt
CEO | Chief Executive Officer | 53 | 31/05/21 |
Marie Svensson
DFI | Director of Finance/CFO | 60 | 31/08/20 |
Chief Tech/Sci/R&D Officer | 56 | 31/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 70 | 31/12/16 | |
Staffan Encrantz
BRD | Director/Board Member | 72 | 08/05/22 |
Director/Board Member | 62 | 31/05/21 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ATORX Stock
- 0RK9 Stock